^
    Back
    Association details:
    Biomarker:DDX39B overexpression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Curr Cancer Drug Targets
    Title:

    DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC

    Published date:
    08/11/2021
    Excerpt:
    Overexpression of DDX39B predicted poor OS of ccRCC patients in SYSU set, TCGA set, and a RECA-EU set. 
    DOI:
    10.2174/1568009621666210811115054